Eureka Therapeutics
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
5858 Horton St Ste 362, Emeryville, Cali...Phone Number
(510) 654-7045Website
www.eurekatherapeutics.comRevenue
$40 MillionIndustry
About Eureka Therapeutics
Eureka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative technology platforms to target cancer-specific treatments, particularly for solid tumors and other malignancies. Their proprietary platforms, E-ALPHA and ARTEMIS, leverage high-throughput screening and T cell therapy to create potential treatment options. The company aims to enhance cancer treatment through a deeper understanding of various cancer types and the application of advanced technologies. Their intended clients include patients suffering from different forms of cancer, as well as healthcare professionals involved in cancer treatment.Explore more
Eureka Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Eureka Therapeutics
Compare insights from companies similar to Eureka Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Eureka Therapeutics Tech Stack
A closer look at the technologies used by Eureka Therapeutics
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Eureka Therapeutics
Sign Up For FreeTo access detailed company insights
Eureka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative technology platforms to target cancer-specific treatments, particularly for solid tumors and other malignancies. Their proprietary platforms, E-ALPHA and ARTEMIS, leverage high-throughput screening and T cell therapy to create potential treatmen... Read More
